SCHEMBL9636980

SCHEMBL9636980

O=c1cc(Cc2nnn[nH]2)oc2cc(COc3ccc(OCc4ccc5ccccc5n4)cc3)ccc12

nearest known ligand 0.57

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CYSLTR1 Q9Y271 5/20 0.50
CYSLTR2 Q9NS75 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9757079 0.82 CYSLTR1 (0.49) CYSLTR1CYSLTR2
SCHEMBL7006454 0.82 CYSLTR1 (0.62) CYSLTR1CYSLTR2
SCHEMBL6090157 0.82 CYSLTR1 (0.62) CYSLTR1CYSLTR2
SCHEMBL10543991 0.82 CYSLTR1 (0.65) CYSLTR1CYSLTR2
SCHEMBL9635460 0.81 CYSLTR1 (0.47) CYSLTR1CYSLTR2
SCHEMBL9829080 0.81 CYSLTR1 (0.64) CYSLTR1CYSLTR2
SCHEMBL7715945 0.80 CYSLTR1 (0.56) CYSLTR1CYSLTR2
SCHEMBL9636892 0.80 CYSLTR1 (0.51) CYSLTR1CYSLTR2
SCHEMBL9635514 0.80 CYSLTR1 (0.47) CYSLTR1CYSLTR2
SCHEMBL6088661 0.79 CYSLTR1 (0.53) CYSLTR1CYSLTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5082849-A Antiinflammatory agents or antiallergens AVENTIS PHARMACEUTICALS INC. 1992-01-21 US disclosed
EP-0434827-A4 QUINOLINYL-BENZOPYRAN DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D 4? 1992-01-08 EP disclosed
EP-0434827-A1 QUINOLINYL-BENZOPYRAN DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D 4? RORER INTERNATIONAL (HOLDINGS), INC. (US) 1991-07-03 EP disclosed
WO-1991001123-A2 QUINOLINYL-BENZOPYRAN DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D¿4? RORER INTERNATIONAL (OVERSEAS) INC. (US) 1991-02-07 WO disclosed
US-4977162-A Quinolinyl-chromone derivatives and use for treatment of hypersensitive ailments RORER PHARMACEUTICAL CORPORATION (US) 1990-12-11 US disclosed